Advance Nanotech and Partners Celebrate Grand Opening of New Research and Development Facility; University of Cambridge's Centre for Advanced Photonics and Electronics Formally Opens Doors
"We are very excited to be a part of the CAPE project. It is a groundbreaking engineering initiative and a promising collaboration between the University and its corporate partners," said Magnus Gittins, CEO of Advance Nanotech. "The engineers within this facility will be working on leading technology developments with the potential to shape the future of our society."
“The engineers within this facility will be working on leading technology developments with the potential to shape the future of our society.”
CAPE is an integrated Research Facility within the Electrical Engineering Department. The Electrical Engineering Department has a staff of 20 academics, 70 post-doctoral researchers, and 170 research students. CAPE is funded by Advance Nanotech, Alps Electric Company Limited, Dow Corning Corporation, and Ericsson Marconi Corporation, and is designed to bring research activities into development and exploitation in close collaboration with industry. The program enables designers and engineers within academia and industry to benefit from the burgeoning developments in advanced photonics and electronics. In the past five years, numerous patents have been filed and ten spin-out companies have been formed from projects which began in the Electrical Division within Cambridge's Department of Engineering.
Advance Nanotech is currently funding 26 nanotechnologies in the electronics, biopharma and materials industries. The firm provides services ranging from funding, to human capital and research equipment essential to ensuring that the most promising companies can accelerate the path to rapid commercialization. In this way, investor exposure to any particular technology is mitigated with Advance Nanotech retaining the option to increase investment in those technologies that successfully mature.
For more information on the CAPE project, or to view photos of the facility, please contact RJ Bardsley or Derek Brookmeyer at 415-623-2085.
About the University of Cambridge
The University of Cambridge's reputation for outstanding academic achievement is known worldwide and reflects the intellectual achievement of its students, as well as the world-class original research carried out by the staff of the University and the Colleges.
As Cambridge approaches its eight hundredth anniversary in 2009, it is looking to the future. It continues to change in response to the challenges it faces. The modern University is an international centre of teaching and research in a vast range of subjects: about half of the students study science or technology. Members of the University have won over sixty Nobel Prizes. For more information, please visit www.cam.ac.uk.
About Advance Nanotech, Inc.
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions. For more information on Advance Nanotech, please visit www.advancenanotech.com.
This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.
Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech's dependence on third parties and partners; and those risks described Advance Nanotech's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.
Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.